Table 1 SABA and ICS prescribing in primary care in England for the 12-months before (April 2021–March 2022) and after (April 2022-March 2023) the Impact and Investment Fund 2022-2023 was introduced, including incentives RESP-062 and ES-02.
Descriptor | All Primary Care Prescribing in England | |
|---|---|---|
Total Prescribing | Pre-IIF April 2021–March 2022 | Post-IIF April 2022–March 2023 |
SABA - n | 25,927,252 | 25,885,213 |
ICS - n | 26,375,509 | 26,883,633 |
Proportion SABA (%) | 50% | 49% |
SABA Prescribing in England | Pre-IIF April 2022–March 2023 | Post-IIF April 2022–March 2023 |
All SABA – n | 25,927,252 | 25,885,213 |
- Salamol™ – n - Ventolin Evohaler™ | 1,322,729 5,528,836 | 4,931,087 4,414,140 |
Salamol as a proportion of all SABA (%) | 5.1% | 19% |
Change in Prescribing Apr 21–Mar 22 to Apr 22–Mar 23 | All Primary Care Prescribing in England | |
SABA | ||
- n - % change (post-IIF vs. pre-IIF) | −42,039 −0.16% | |
-Salamol | ||
- n - % change (post-IIF vs. pre-IIF) | +3,608,358# +273% | |
-Ventolin Evohaler | ||
- n - % change (post-IIF vs. pre-IIF) | −1,114,696# −20% | |
ICS | ||
- n - % change from prior 12-months | +508,124** +1.93% | |
Proportion SABA (%) | −0.52% | |
